Global Longlife Hospital and Research Ltd (543520)
Latest quarterly results (H2 FY26)
In its latest reported quarter, H2 FY26, Global Longlife's revenue was ₹0.0 Cr, and net profit ₹-0.4 Cr (a smaller loss than a year earlier).
| H2 FY26 (₹ Cr) | Value | YoY vs H2 FY25 | vs prev. half |
|---|---|---|---|
| Revenue | ₹0.0 | — | — |
| Operating profit | ₹-0.4 | loss widened | loss narrowed |
| Net profit | ₹-0.4 | loss narrowed | loss narrowed |
| EPS (₹) | -0.38 | loss narrowed | loss narrowed |
📢 Recent Corporate Announcements
Global Longlife Hospital and Research Ltd has scheduled an Extra-Ordinary General Meeting (EGM) on October 30, 2026, to ratify the submission of a CA certificate for changing its name to Asahi Enterprise Limited. According to the certificate under SEBI LODR Regulation 45, the company has deployed ₹1,702.15 Lakhs (₹17.02 Cr), classified as cash and cash equivalents, into a new activity or project, representing 71.73% of total assets (₹2,372.98 Lakhs). This pivot comes alongside a change in its main business object as previous hospital operations shrunk to zero revenue in recent quarters.
- EGM scheduled on Friday, October 30, 2026, at 12:15 P.M. IST via VC/OAVM.
- Special resolution to ratify the CA certificate for changing company name to Asahi Enterprise Limited.
- Investment in new activity stands at ₹1,702.15 Lakhs, representing 71.73% of total assets of ₹2,372.98 Lakhs.
- Investment in new activity exceeds the regulatory minimum threshold of 50% (₹1,186.49 Lakhs).
Asahi Enterprise Limited (formerly Global Longlife Hospital and Research Ltd) announced that its Board of Directors met on October 3, 2026, and approved convening an Extra-Ordinary General Meeting (EGM) on October 30, 2026. The EGM will seek shareholder approval for an unspecified 'issuance' referenced in the filing. The company also appointed NSDL for remote e-voting and M/s Insiya Nalawala & Associates as the scrutinizer. The company has a tiny market capitalization of Rs 16 crore and reported negative TTM PAT of Rs -2 crore with zero revenue in recent quarters.
- Board approved convening the First EGM of FY 2026-2027 on Friday, October 30, 2026 at 12:15 P.M. IST
- EGM will seek member approval for an 'issuance' (details to be in EGM notice)
- M/s Insiya Nalawala & Associates appointed as scrutinizer for remote e-voting
- NSDL appointed as the remote e-voting agency for the scheduled EGM
Abhishek Ashvinbhai Kamdar HUF has acquired a 5.09% stake in Global Longlife Hospital and Research Ltd via open market transactions on September 25, 2026. The acquisition involves 5,35,000 equity shares out of the total voting share capital of 1,05,00,000 shares. Prior to this transaction, the acquirer held zero shares in the company. This substantial acquisition occurs against a backdrop of declining promoter shareholding, which dropped to 22.88% by March 2026.
- Acquisition of 5,35,000 equity shares representing 5.09% voting capital
- Pre-transaction holding was nil (0.00%)
- Transaction conducted via open market on September 25, 2026
- Total paid-up and voting equity capital remains 1,05,00,000 shares of Rs 10 each
Global Longlife Hospital and Research Ltd has received Ministry of Corporate Affairs (MCA) approval for Form MGT-14 to alter its Main Objects Clause effective August 25, 2026. The amendment expands the company's scope significantly beyond hospital operations into trading and processing of agricultural produce, food commodities, apparel, textiles, and bullion/precious metals. This pivot comes amid weak financials, with TTM revenue at Rs 1 Cr, net losses of Rs -2 Cr, and promoter holding declining to 22.88% in March 2026.
- MCA approval received for Form MGT-14 with effect from August 25, 2026
- Main Objects expanded to cover food products, grains, spices, oilseeds, and agro produce
- Scope broadened to include apparel, garments, textiles, and precious metals/bullion trading
- Company market cap stands at Rs 11 Cr with TTM revenue of Rs 1 Cr
Dhruv Sureshkumar Jani, a member of the promoter group, sold 7,22,000 equity shares (6.88% stake) in the open market between August 10 and August 12, 2026. This transaction has effectively liquidated his position, reducing his holding from 6.89% to just 0.01%. This sale is significant given the company's micro-cap status (Rs 13 Cr) and the existing downward trend in total promoter holding, which dropped from 55.1% in September 2025 to 22.88% in March 2026. The company is currently struggling financially, reporting near-zero revenue and a net loss of Rs 2 Cr for the trailing twelve months.
- Sale of 7,22,000 equity shares representing 6.88% of the total voting capital
- Seller's residual holding reduced to 990 shares or 0.01% post-transaction
- Transaction executed via open market between August 10, 2026, and August 12, 2026
- Total equity share capital remains at 1,05,00,000 shares of Rs 10 each
- Promoter group holding has seen a sharp decline from 55.1% in Sep 2025 to 22.88% in Mar 2026
Dhruv Sureshkumar Jani, a member of the promoter group, sold 10,00,000 equity shares representing a 9.52% stake in Global Longlife Hospital and Research Ltd. The transaction occurred in the open market between August 6 and August 7, 2026. This sale reduced the individual's holding from 16.41% to 6.89%. This follows a significant downward trend in total promoter holding, which fell from 55.1% in September 2025 to 22.88% by March 2026.
- Sale of 10,00,000 equity shares, equivalent to 9.52% of the company's total voting capital
- Individual promoter group holding reduced from 17,22,990 shares (16.41%) to 7,22,990 shares (6.89%)
- Disposal executed through open market transactions on August 6 and August 7, 2026
- Company total equity share capital remains at 1,05,00,000 shares of Rs 10 each
Dhruv Sureshkumar Jani, a member of the promoter group, sold 6,78,000 equity shares of Global Longlife Hospital and Research Ltd between July 01 and July 30, 2026. This open-market transaction represents a 6.46% stake in the company, reducing the seller's individual holding from 22.87% to 16.41%. This sale occurs against a backdrop of deteriorating financials, with the company reporting a TTM loss of Rs 2 Cr and a significant decline in total promoter holding from 55.1% in September 2025 to 22.88% in March 2026.
- Sale of 6,78,000 equity shares representing 6.46% of the total share capital
- Seller's individual holding reduced from 22.87% to 16.41% post-transaction
- Transactions executed via open market between July 01, 2026, and July 30, 2026
- Company market capitalization remains low at approximately Rs 12 Cr
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
